The Warburg effect: a balance of flux analysis

Metabolomics

Volumn 11, Issue 4, 2015, Pages 787-796

  Vaitheesvaran, B ^a   Xu, J ^b   Yee, J ^c   Lu, Q Y ^c   Go, V L ^c   Xiao, G G ^d,e   Lee, W N ^c,f  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^e DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^f LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

Anaplerosis; Energy metabolism; Metabolic compartments; Metabolic phenotype; Tracer based metabolomics

Indexed keywords

GLUCOSE 6 PHOSPHATE DEHYDROGENASE;

AEROBIC METABOLISM; CANCER CHEMOTHERAPY; CITRIC ACID CYCLE; ENERGY METABOLISM; ENERGY YIELD; GLYCOLYSIS; HUMAN; METABOLIC FLUX ANALYSIS; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PENTOSE PHOSPHATE CYCLE; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; WALKER WARBURG SYNDROME;

EID: 84931570411     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-014-0760-9     Document Type: Review

References (53)

1. Boren, J., et al. (2001). Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. Journal of Biological Chemistry,276, 37747–37753.
2. Boren, J., et al. (2003). The stable isotope-based dynamic metabolic profile of butyrate-induced HT29 cell differentiation. Journal of Biological Chemistry,278, 28395–28402. doi:10.1074/jbc.M302932200.
3. Boros, L. G., Torday, J. S., Lim, S., Bassilian, S., Cascante, M., & Lee, W. N. (2000). Transforming growth factor beta2 promotes glucose carbon incorporation into nucleic acid ribose through the nonoxidative pentose cycle in lung epithelial carcinoma cells. Cancer Research,60, 1183–1185.
4. Boros, L. G., Bassilian, S., Lim, S., & Lee, W. N. (2001). Genistein inhibits nonoxidative ribose synthesis in MIA pancreatic adenocarcinoma cells: a new mechanism of controlling tumor growth. Pancreas,22, 1–7.
5. Boros, L. G., Cascante, M., & Lee, W. N. (2002a). Metabolic profiling of cell growth and death in cancer: Applications in drug discovery. Drug Discovery Today,7, 364–372.
6. Boros, L. G., Lee, W. N., & Go, V. L. (2002b). A metabolic hypothesis of cell growth and death in pancreatic cancer. Pancreas,24, 26–33.
7. Boros, L. G., Torday, J. S., Lee, W. N., & Rehan, V. K. (2002c). Oxygen-induced metabolic changes and transdifferentiation in immature fetal rat lung lipofibroblasts. Molecular Genetics and Metabolism,77, 230–236.
8. Boros, L. G., Steinkamp, M. P., Fleming, J. C., Lee, W. N., Cascante, M., & Neufeld, E. J. (2003). Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA). Blood,102, 3556–3561. doi:10.1182/blood-2003-05-1537.
9. Chaturvedi, A., et al. (2013). Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood,122, 2877–2887. doi:10.1182/blood-2013-03-491571.
10. Chen, C., et al. (2013). Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes & Development,27, 1974–1985. doi:10.1101/gad.226613.113.
11. Comin-Anduix, B., et al. (2001). The effect of thiamine supplementation on tumour proliferation. A metabolic control analysis study. European Journal of Biochemistry,268, 4177–4182.
12. D’Alessandro, A., & Zolla, L. (2012). Metabolomics and cancer drug discovery: Let the cells do the talking. Drug Discovery Today,17, 3–9. doi:10.1016/j.drudis.2011.09.017.
13. Edwards, J. S., Ramakrishna, R., & Palsson, B. O. (2002). Characterizing the metabolic phenotype: A phenotype phase plane analysis. Biotechnology and Bioengineering,77, 27–36.
14. Faubert, B., et al. (2013). AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metabolism,17, 113–124. doi:10.1016/j.cmet.2012.12.001.
15. Feng, Z., & Levine, A. J. (2010). The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends in Cell Biology,20, 427–434. doi:10.1016/j.tcb.2010.03.004.
16. Ferreira, L. M. (2010). Cancer metabolism: the Warburg effect today. Experimental and Molecular Pathology,89, 372–380. doi:10.1016/j.yexmp.2010.08.006.
17. Harris, D. M., Li, L., Chen, M., Lagunero, F. T., Go, V. L., & Boros, L. G. (2012). Diverse mechanisms of growth inhibition by luteolin, resveratrol, and quercetin in MIA PaCa-2 cells: A comparative glucose tracer study with the fatty acid synthase inhibitor C75. Metabolomics,8, 201–210. doi:10.1007/s11306-011-0300-9.
18. Katz, J., & McGarry, J. D. (1984). The glucose paradox. Is glucose a substrate for liver metabolism? Journal of Clinical Investigation,74, 1901–1909. doi:10.1172/jci111610.
19. Katz, J., Lee, W. N., Wals, P. A., & Bergner, E. A. (1989). Studies of glycogen synthesis and the Krebs cycle by mass isotopomer analysis with [U-13C]glucose in rats. Journal of Biological Chemistry,264, 12994–13004.
20. Katz, J., Wals, P., & Lee, W. N. (1993). Isotopomer studies of gluconeogenesis and the Krebs cycle with 13C-labeled lactate. Journal of Biological Chemistry,268, 25509–25521.
21. Kim, J.-W., Gardner, L. B., & Dang, C. V. (2005). Oncogenic alterations of metabolism and the Warburg effect. Drug Discovery Today: Disease Mechanisms,2, 233–238. doi:10.1016/j.ddmec.2005.04.001.
22. Kurland, I. J., Alcivar, A., Bassilian, S., & Lee, W. N. (2000). Loss of [13C]glycerol carbon via the pentose cycle. Implications for gluconeogenesis measurement by mass isotoper distribution analysis. Journal of Biological Chemistry,275, 36787–36793. doi:10.1074/jbc.M004739200.
23. Lee, W. N. (1993). Appendix. Analysis of tricarboxylic acid cycle using mass isotopomer ratios. Journal of Biological Chemistry,268, 25522–25526.
24. Lee, W. N. (2006). Characterizing phenotype with tracer based metabolomics. Metabolomics,2, 31–39. doi:10.1007/s11306-006-0017-3.
25. Lee, W. N., Boros, L. G., Puigjaner, J., Bassilian, S., Lim, S., & Cascante, M. (1998). Mass isotopomer study of the nonoxidative pathways of the pentose cycle with [1,2-13C2]glucose. American Journal of Physiology,274, E843–E851.
26. Lee, W. N., Edmond, J., Bassilian, S., & Morrow, J. W. (1996). Mass isotopomer study of glutamine oxidation and synthesis in primary culture of astrocytes. Developmental Neuroscience,18, 469–477.
27. Lee, W. N., & Go, V. L. (2005). Nutrient-gene interaction: Tracer-based metabolomics. Journal of Nutrition,135, 3027S–3032S.
28. Lee, W. N., Guo, P., Lim, S., Bassilian, S., Lee, S. T., Boren, J., et al. (2004). Metabolic sensitivity of pancreatic tumour cell apoptosis to glycogen phosphorylase inhibitor treatment. British Journal of Cancer,91, 2094–2100. doi:10.1038/sj.bjc.6602243.
29. Lee, W. N., Wahjudi, P. N., Xu, J., & Go, V. L. (2010). Tracer-based metabolomics: concepts and practices. Clinical Biochemistry,43, 1269–1277. doi:10.1016/j.clinbiochem.2010.07.027.
30. Levine, A. J., & Puzio-Kuter, A. M. (2010). The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science,330, 1340–1344. doi:10.1126/science.1193494.
31. Lu, Q.-Y., Zhang, L., Yee, J., Go, V.-L., & Lee, W.-N. (2014). Metabolic consequences of LDHA inhibition by epigallocatechin gallate and oxamate in MIA PaCa-2 pancreatic cancer cells. Metabolomics. doi:10.1007/s11306-014-0672-8.
32. Ma, D., et al. (2012). Inhibition of glycogen phosphorylation induces changes in cellular proteome and signaling pathways in MIA pancreatic cancer cells. Pancreas,41, 397–408. doi:10.1097/MPA.0b013e318236f022.
33. Malloy, C. R., Sherry, A. D., & Jeffrey, F. M. (1990). Analysis of tricarboxylic acid cycle of the heart using 13C isotope isomers. American Journal of Physiology,259, H987–H995.
34. Marin, S., et al. (2004). Dynamic profiling of the glucose metabolic network in fasted rat hepatocytes using [1,2-13C2]glucose. Biochemical Journal,381, 287–294. doi:10.1042/bj20031737.
35. Orth, J. D., Thiele, I., & Palsson, B. O. (2010). What is flux balance analysis? Nature Biotechnology,28, 245–248. doi:10.1038/nbt.1614.
36. Rais, B., et al. (1999). Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich’s tumor cells through inhibition of the pentose cycle. FEBS Letters,456, 113–118.
37. Ramos-Montoya, A., et al. (2006). Pentose phosphate cycle oxidative and nonoxidative balance: A new vulnerable target for overcoming drug resistance in cancer. International Journal of Cancer,119, 2733–2741. doi:10.1002/ijc.22227.
38. Reed, J. L., & Palsson, B. O. (2003). Thirteen years of building constraint-based in silico models of Escherichia coli. Journal of Bacteriology,185, 2692–2699.
39. Rehan, V. K., et al. (2007). In utero nicotine exposure alters fetal rat lung alveolar type II cell proliferation, differentiation, and metabolism. American Journal of Physiology. Lung Cellular and Molecular Physiology,292, L323–L333. doi:10.1152/ajplung.00071.2006.
40. Reitman, Z. J., et al. (2014). Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. Journal of Biological Chemistry,289, 23318–23328. doi:10.1074/jbc.M114.575183.
41. Schilling, C. H., & Palsson, B. O. (1998). The underlying pathway structure of biochemical reaction networks. Proceedings of the National Academy of Science USA,95, 4193–4198.
42. Schilling, C. H., Letscher, D., & Palsson, B. O. (2000). Theory for the systemic definition of metabolic pathways and their use in interpreting metabolic function from a pathway-oriented perspective. Journal of Theoretical Biology,203, 229–248. doi:10.1006/jtbi.2000.1073.
43. Selivanov, V. A., et al. (2004). An optimized algorithm for flux estimation from isotopomer distribution in glucose metabolites. Bioinformatics,20, 3387–3397. doi:10.1093/bioinformatics/bth412.
44. Selivanov, V. A., et al. (2005). Rapid simulation and analysis of isotopomer distributions using constraints based on enzyme mechanisms: An example from HT29 cancer cells. Bioinformatics,21, 3558–3564. doi:10.1093/bioinformatics/bti573.
45. Turcan, S., et al. (2013). Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget,4, 1729–1736.
46. Upadhyay, M., Samal, J., Kandpal, M., Singh, O. V., & Vivekanandan, P. (2013). The Warburg effect: Insights from the past decade. Pharmacology & Therapeutics,137, 318–330. doi:10.1016/j.pharmthera.2012.11.003.
47. Vaitheesvaran, B., et al. (2014). Role of the tumor suppressor IQGAP2 in metabolic homeostasis: Possible link between diabetes and cancer. Metabolomics,10, 920–937. doi:10.1007/s11306-014-0639-9.
48. Vizan, P., et al. (2005). K-ras codon-specific mutations produce distinctive metabolic phenotypes in NIH3T3 mice [corrected] fibroblasts. Cancer Research,65, 5512–5515. doi:10.1158/0008-5472.can-05-0074.
49. Wang, J., et al. (2013). Inhibition of transketolase by oxythiamine altered dynamics of protein signals in pancreatic cancer cells. Experimental Hematology & Oncology,2, 18. doi:10.1186/2162-3619-2-18.
50. Xu, J., Lee, W. N., Phan, J., Saad, M. F., Reue, K., & Kurland, I. J. (2006). Lipin deficiency impairs diurnal metabolic fuel switching. Diabetes,55, 3429–3438. doi:10.2337/db06-0260.
51. Yang, Y., et al. (2013). Metabolic reprogramming for producing energy and reducing power in fumarate hydratase null cells from hereditary leiomyomatosis renal cell carcinoma. PLoS ONE,8, e72179. doi:10.1371/journal.pone.0072179.
52. Zhang, H., et al. (2010). Inhibition of protein phosphorylation in MIA pancreatic cancer cells: Confluence of metabolic and signaling pathways. Journal of Proteome Research,9, 980–989. doi:10.1021/pr9008805.
53. Zheng, J. (2012). Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review). Oncology Letters,4, 1151–1157. doi:10.3892/ol.2012.928.